MOTS-c

What it is

MOTS-c is a mitochondrial-derived peptide first described in 2015 by Lee and colleagues in Cell Metabolism^{[9 ]}. The name stands for mitochondrial open reading frame of the 12S rRNA-c. Unlike most peptide hormones, which are encoded in nuclear DNA, MOTS-c is proposed to originate from a short open reading frame within mitochondrial DNA and to function as a metabolic signal between mitochondria, the nucleus, and peripheral tissues^{[9 –11 ]}.

Chemical structure

MOTS-c is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR and molecular formula C101H152N28O22S2^{[1 ]}. It has been studied mainly for metabolic signaling, AMPK-related pathways, insulin sensitivity, exercise response, and age-related muscle homeostasis^{[9 –14 ]}.

Mechanism

The discovery paper reported that MOTS-c affected glucose metabolism and metabolic homeostasis in mice, with skeletal muscle identified as a major target tissue^{[9 ]}. Mechanistic work has focused on inhibition of the folate cycle and de novo purine biosynthesis, activation of AMPK, nuclear translocation during metabolic stress, and downstream changes in stress-response gene expression^{[9 –11 ]}. These pathways are biologically plausible for metabolic disease research, but they do not establish MOTS-c as a human therapy.

MOTS-c is commonly described in public discourse as an “exercise mimetic,” a phrase derived from studies showing that endogenous MOTS-c changes with exercise and that exogenous MOTS-c affects physical performance or muscle metabolism in animal models^{[12 –14 ]}. This framing can be misleading if it implies that an injected peptide has the same safety, efficacy, and physiologic complexity as exercise in humans. Current evidence supports MOTS-c as a research target, not an approved substitute for exercise or a validated weight-loss drug.

When sold online, MOTS-c is usually presented as an injectable research peptide for energy, endurance, weight management, body composition, or longevity. No FDA-approved MOTS-c product exists, and there is no approved dose, route, indication, contraindication profile, or long-term safety label^{[2 –7 ]}. A Phase 2a MOTS-c trial in adults with prediabetes and overweight or obesity was listed as recruiting in 2026, but no results had been posted as of this draft^{[15 ]}.

Regulatory status

MOTS-c is not FDA-approved for any indication. No FDA-approved prescription product containing MOTS-c was identified in FDA materials reviewed for this draft^{[2 –7 ]}. Clinical trial registration for MOTS-c or MOTS-c analogs does not equal FDA approval^{[15 –16 ]}.

April 2026 503A removal — procedural, not authorization

Under section 503A, state-licensed pharmacies and physicians may compound using a bulk drug substance only if the substance complies with an applicable USP/NF monograph, is a component of an FDA-approved drug product if no monograph exists, or appears on FDA’s 503A bulks list^{[2 ]}. FDA’s April 22, 2026 503A update states that “MOTs-C” was removed from Category 2 because the nomination was withdrawn and that FDA intends to consult the Pharmacy Compounding Advisory Committee on July 23, 2026 regarding possible inclusion of MOTS-c acetate and MOTS-c free base on the 503A bulks list^{[3 ]}.

Removal from Category 2 is not FDA approval and does not itself authorize compounding. MOTS-c is not listed in 503A Category 1 in the April 22, 2026 document and was not identified on the 503A bulks list reviewed for this draft^{[2 –3 ]}. FDA’s July 2026 agenda identifies obesity and osteoporosis as the uses to be evaluated for MOTS-c-related bulk substances^{[4 ]}.

503B and FDA safety-risk listing

Under section 503B, outsourcing facilities may compound from bulk drug substances only if the substance appears on FDA’s 503B bulks list or the compounded drug appears on FDA’s shortage list at the time of compounding, distribution, and dispensing^{[6 ]}. MOTS-c was not identified on the FDA 503B bulks list reviewed for this draft^{[7 ]}.

FDA’s safety-risk page lists MOTs-C among withdrawn nominated substances and states that compounded drugs containing MOTs-C may pose immunogenicity risk and peptide-related impurity or API-characterization complexities, and that FDA had not identified human exposure data for drug products containing MOTs-C^{[5 ]}. FDA therefore stated that it lacked important safety information, including whether the drug would harm humans^{[5 ]}.

Controlled-substance and anti-doping status

MOTS-c was not identified in the federal controlled-substance schedules in 21 CFR Part 1308 as reviewed for this draft^{[8 ]}. For athletes, USADA states that MOTS-c is prohibited at all times under the WADA Prohibited List as an AMPK activator under Section S4.4.1, and that athletes cannot obtain a therapeutic use exemption because there is no approved therapeutic use^{[17 ]}.

Date of last regulatory verification: May 5, 2026.

Research summary

The foundational MOTS-c paper reported that the peptide promoted metabolic homeostasis and reduced obesity and insulin resistance in mouse models^{[9 ]}. In that study, MOTS-c was described as a mitochondrial DNA-encoded signaling peptide with skeletal muscle as a major target; experiments suggested AMPK activation after inhibition of the folate cycle and de novo purine biosynthesis^{[9 ]}. These findings are important for mechanism, but they are preclinical.

Mitochondrial-derived peptide context

Several reviews have framed MOTS-c as part of a broader class of mitochondrial-derived peptides, alongside humanin and SHLP peptides^{[10 –11 ]}. These reviews describe MOTS-c as a stress-responsive peptide that may move to the nucleus and affect nuclear gene expression under metabolic stress^{[10 –11 ]}. Such reviews are useful for biology, but they generally conclude that clinical translation remains early and that no established therapeutic application has been developed^{[10 –11 ]}.

Exercise and aging

Exercise and aging research provides some human biomarker data. Reynolds and colleagues reported that MOTS-c is exercise-induced and studied late-life intermittent MOTS-c treatment in mice, with effects on physical capacity and age-dependent muscle homeostasis^{[12 ]}. The same paper reported changes in endogenous MOTS-c in human skeletal muscle and circulation after exercise^{[12 ]}. Dieli-Conwright and colleagues studied exercise effects on MOTS-c among breast cancer survivors, supporting interest in MOTS-c as a metabolic biomarker rather than a proven treatment^{[13 ]}.

Other preclinical models

MOTS-c has also been studied in preclinical models of postmenopausal metabolic dysfunction, cold adaptation, neuropathic pain, and muscle atrophy signaling^{[14 ,18 –19 ]}. For example, Lu and colleagues reported that MOTS-c affected adipose homeostasis in ovariectomized mice, while Jiang and colleagues studied neuropathic pain in mice through AMPK-related mechanisms^{[14 ,19 ]}. These animal findings should not be extrapolated into human claims for weight loss, pain treatment, menopause, osteoporosis, or athletic performance.

Where the human evidence ends

Human interventional evidence is currently limited. A Phase 2a randomized, double-blind, placebo-controlled study of investigational MOTS-c in adults with prediabetes and overweight or obesity was listed as recruiting in 2026, with estimated enrollment of 120 and no results posted^{[15 ]}. A separate completed Phase 1a/1b study evaluated CB4211, an analog of MOTS-c, in healthy non-obese subjects and subjects with nonalcoholic fatty liver disease; ClinicalTrials.gov lists the study as completed with 88 participants, but this was an analog and not consumer MOTS-c^{[16 ]}. Company-reported topline results for CB4211 should be treated as investigational and not as proof that MOTS-c itself is safe or effective^{[20 ]}.

Overall, MOTS-c has strong mechanistic interest and a growing preclinical literature, but as of 2026-05-05 no completed, peer-reviewed, large randomized human efficacy trial was identified for MOTS-c itself. Claims that MOTS-c treats obesity, osteoporosis, insulin resistance, sarcopenia, chronic fatigue, longevity, or athletic performance are not established by approval-quality human evidence.

Public discourse

Robert F. Kennedy Jr., US Secretary of Health and Human Services, discussed peptides broadly in the context of FDA compounding restrictions; his comments were not a clinical assessment of MOTS-c specifically^{[21 ]}.

Will Stone, NPR health correspondent, named MOTS-c among unapproved peptides affected by FDA compounding restrictions and described the regulatory debate^{[22 ]}.

Eric Topol, MD, Scripps Research Translational Institute, criticized loosening access to unapproved peptides without stronger clinical evidence^{[23 ]}.

Beth Mole, PhD, senior health reporter at Ars Technica, named MOTS-c among the seven peptides scheduled for PCAC review and emphasized that FDA’s listed uses do not equal proven uses^{[24 ]}.

The U.S. Anti-Doping Agency framed MOTS-c as an experimental and prohibited peptide for athletes^{[17 ]}.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

MOTS-c has no FDA-approved prescribing information. There is therefore no FDA-reviewed label establishing contraindications, common adverse reactions, drug interactions, pregnancy or lactation safety, carcinogenicity data, or long-term monitoring recommendations^{[2 –7 ]}.

Compounding-related risks

FDA’s compounding safety concerns include potential immunogenicity, peptide-related impurity concerns, and API characterization complexity^{[5 ]}. These issues are particularly relevant for injectable products, where sterility, endotoxin control, purity, concentration, and sequence identity are central safety questions.

USADA-reported user reports

USADA states that conditions for safe use are unknown because no completed clinical trials had established safety, and notes reports among purported online users including increased heart rate or palpitations, injection-site irritation, insomnia, and fever^{[17 ]}. These reports are not a controlled adverse-event dataset, but they illustrate the uncertainty around gray-market use.

Mechanism-based concerns

Theoretical risks follow from the proposed biology. MOTS-c is studied for AMPK activation, glucose metabolism, mitochondrial stress signaling, muscle metabolism, and inflammatory pathways^{[9 –14 ]}. In humans, manipulating these pathways could plausibly interact with diabetes medications, cardiovascular disease, cancer biology, pregnancy, inflammatory disease, or exercise physiology, but formal interaction and contraindication data are not available.

Long-term safety data are limited. Existing preclinical studies and early investigational trials do not establish decades-long safety, safety in medically complex patients, or safety of nonclinical products sold online as “research use only.”

Available through

MOTS-c is not currently available through routine FDA-compliant prescription or compounding channels in the United States as of 2026-05-05^{[2 –7 ]}. It is not FDA-approved, is not on the 503A or 503B bulks lists, and awaits PCAC review scheduled for July 23, 2026^{[3 –4 ]}.

ProPeptideGuide does not link to or endorse grey-market vendors, research-chemical sellers, online peptide shops, or clinics advertising MOTS-c for weight loss, energy, performance, endurance, anti-aging, or metabolic optimization.